Abstract
Equine herpesvirus-1 is a cause of outbreaks of abortion and neurological disease. The pathogenesis of both these diseases depends on establishment of viremia. An experiment was performed to determine the protective efficacy of two commercially available vaccines used with an optimized 3-dose vaccination regime: a modified-live viral (MLV) and a high antigen load killed vaccine licensed for abortion control. The study design was a blinded, randomized challenge trial. Three groups of 8 yearling ponies received one of three treatments: MLV vaccine (Rhinomune®, Boehringer Ingelheim Vetmedica, Inc.); killed vaccine (Pneumabort-K®, Pfizer Animal Health); or a placebo (control group). Three vaccinations were administered at intervals of 27 and 70 days followed by challenge infection 24 days later. Clinical disease after challenge was significantly reduced in both vaccine groups; the reduction was greater in the MLV vaccine group. Nasal shedding was reduced by at least 1-2 logs in both vaccine groups. The number of days of viremia was significantly reduced in the killed vaccine group only. This study demonstrated that both commercial vaccines significantly suppressed EHV-1 disease and nasal viral shedding, and one vaccine suppressed days of viremia.
Original language | English |
---|---|
Pages (from-to) | 5203-5211 |
Number of pages | 9 |
Journal | Vaccine |
Volume | 28 |
Issue number | 32 |
DOIs | |
State | Published - Jul 2010 |
Bibliographical note
Funding Information:This project was funded by Fort Dodge Animal Health.
Keywords
- EHV-1
- Horses
- Immunity
- Vaccination
ASJC Scopus subject areas
- Molecular Medicine
- Immunology and Microbiology (all)
- Veterinary (all)
- Public Health, Environmental and Occupational Health
- Infectious Diseases